迪安诊断(300244) - 2022 Q1 - 季度财报

Financial Performance - The company reported a revenue of CNY 4.65 billion for Q1 2022, representing a 62.08% increase compared to CNY 2.87 billion in the same period last year[4] - Net profit attributable to shareholders reached CNY 753.71 million, a 122.62% increase from CNY 338.56 million year-on-year[4] - The net profit excluding non-recurring gains and losses was CNY 747.65 million, up 125.60% from CNY 331.40 million in the previous year[4] - Total operating revenue for the first quarter reached ¥4,648,818,816.20, a significant increase from ¥2,868,272,037.86 in the previous year, representing a growth of approximately 62.1%[27] - Net profit for the quarter was ¥916,645,324.39, compared to ¥412,313,510.21 in the same period last year, reflecting a growth of approximately 122.3%[30] - Total comprehensive income attributable to the parent company was CNY 753,710,562.37, up from CNY 338,559,466.66 in the previous period, representing a growth of approximately 122.3%[33] - Basic earnings per share increased to CNY 1.2148 from CNY 0.5457, reflecting a rise of about 122.3%[33] Cash Flow and Liquidity - The company's cash flow from operating activities was negative at CNY -973.14 million, a decline of 136.81% compared to CNY -410.93 million in the same period last year[4] - Net cash flow from operating activities was negative at CNY -973,140,105.33, compared to CNY -410,932,425.84 in the previous period, indicating a worsening cash flow situation[34] - Cash inflow from operating activities totaled CNY 2,841,260,124.16, an increase from CNY 2,438,043,863.96 year-over-year[34] - Cash outflow for purchasing goods and services was CNY 2,342,881,410.10, up from CNY 1,791,932,468.72, marking a rise of approximately 30.7%[34] - The ending cash and cash equivalents balance was CNY 1,449,166,159.37, down from CNY 1,561,552,524.76, reflecting a decrease of approximately 7.2%[40] Assets and Liabilities - Total assets increased by 12.51% to CNY 17.54 billion compared to CNY 15.59 billion at the end of the previous year[4] - Total liabilities rose to ¥9,118,653,470.41, up from ¥8,118,148,058.94, which is an increase of approximately 12.3%[25] - The total current assets of the company at the end of the reporting period are approximately RMB 12.72 billion, an increase from RMB 10.85 billion at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,710, with the largest shareholder, Chen Haibin, holding 26.38% of shares[12] - The company has pledged 122,744,200 shares held by Chen Haibin, which represents a significant portion of his holdings[12] - The total number of shares held by the top ten shareholders accounts for a substantial portion of the company's equity, with the top shareholder holding over 26%[12] Research and Development - The company’s R&D expenses increased by 52.63% to CNY 115.04 million, reflecting a commitment to enhancing innovation capabilities[8] - Research and development expenses for the quarter were ¥115,038,434.41, compared to ¥75,368,826.63 in the previous year, indicating a year-over-year increase of approximately 52.7%[30] Investment and Financing - The company has successfully completed a loan agreement with the International Finance Corporation (IFC) for up to USD 150 million, enhancing its financial flexibility[17] - The company raised CNY 1,691,368,000.00 in borrowings, an increase from CNY 1,516,795,494.40 in the previous period[40] - The company has engaged in a stock buyback program, purchasing 714,200 shares at an average price of RMB 29.40 per share, totaling approximately RMB 21 million[19] Inventory and Receivables - Accounts receivable increased significantly to approximately RMB 8.35 billion, compared to RMB 6.29 billion at the beginning of the year, indicating a growth of about 32.6%[19] - Inventory at the end of the reporting period is approximately RMB 1.53 billion, up from RMB 1.33 billion, reflecting an increase of about 15.5%[19]